乳房切除术后放疗与淋巴结阳性男性乳腺癌生存改善相关:一项人群分析
本研究基于SEER数据库1998至2013年1933例接受改良根治术的局部或区域非转移性男性乳腺癌患者,回顾性分析术后放疗(PMRT)对总生存的影响。未匹配队列5年OS无差异(78% vs 77%,P=.371),但病例匹配分析中PMRT与5年OS改善相关(83% vs 54%,P<.001)。亚组分析显示,1-3枚阳性淋巴结和4枚以上阳性淋巴结患者中PMRT均与OS改善相关。
要点
- 病例匹配分析中PMRT与5年OS改善相关(83% vs 54%,P<.001)。
- 未匹配队列中PMRT与1-3枚阳性淋巴结患者5年OS改善相关(79% vs 72%,P=.05)。
- 未匹配队列中PMRT与4枚以上阳性淋巴结患者5年OS改善相关(73% vs 53%,P<.001)。
核心结论
- 淋巴结阳性男性乳腺癌接受PMRT可能带来生存获益。
研究设计与样本
- 回顾性队列研究,查询SEER数据库8.3.2版,纳入1998至2013年20岁以上接受改良根治术的局部或区域非转移性浸润性导管/小叶癌男性患者,共1933例。
主要发现
- 未匹配队列中PMRT组与非PMRT组5年OS无差异(78% vs 77%,P=.371)。
- 病例匹配队列中PMRT组5年OS优于非PMRT组(83% vs 54%,P<.001)。
- 未匹配队列亚组分析中,1-3枚阳性淋巴结患者PMRT组5年OS为79% vs 72%(P=.05),4枚以上阳性淋巴结患者为73% vs 53%(P<.001)。
临床怎么用
- 对于淋巴结阳性的男性乳腺癌患者,在改良根治术后可考虑辅助PMRT以改善生存。
局限性
- 由于男性乳腺癌罕见,缺乏随机试验,本研究为回顾性SEER数据库分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Because of its rarity, there are no randomized trials investigating postmastectomy radiation therapy (PMRT) in male breast cancer. This study retrospectively examines the impact of PMRT in male breast cancer patients in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. METHODS AND MATERIALS: The SEER database 8.3.2 was queried for men ages 20+ with a diagnosis of localized or regional nonmetastatic invasive ductal/lobular carcinoma from 1998 to 2013. Included patients were treated by modified radical mastectomy (MRM), with or without adjuvant external beam radiation. Univariate and multivariate analyses evaluated predictors for PMRT use after MRM. Kaplan-Meier overall survival (OS) curves of the entire cohort and a case-matched cohort were calculated and compared by the log-rank test. Cox regression was used for multivariate survival analyses. RESULTS: A total of 1933 patients were included in the unmatched cohort. There was no difference in 5-year OS between those who received PMRT and those who did not (78% vs 77%, respectively, P=.371); however, in the case-matched analysis, PMRT was associated with improved OS at 5 years (83% vs 54%, P<.001). On subset analysis of the unmatched cohort, PMRT was associated with improved OS in men with 1 to 3 positive nodes (5-year OS 79% vs 72% P=.05) and those with 4+ positive nodes (5-year OS 73% vs 53% P<.001). On multivariate analysis of the unmatched cohort, independent predictors for improved OS were use of PMRT: HR=0.551 (0.412-0.737) and estrogen receptor-positive disease: HR=0.577 (0.339-0.983). Predictors for a survival detriment were higher grade 3/4: HR=1.825 (1.105-3.015), larger tumor T2: HR=1.783 (1.357-2.342), T3/T4: HR=2.683 (1.809-3.978), higher N-stage: N1 HR=1.574 (1.184-2.091), N2/N3: HR=2.328 (1.684-3.218), black race: HR=1.689 (1.222-2.336), and older age 81+: HR=4.164 (1.497-11.582). CONCLUSIONS: There may be a survival benefit with the addition of PMRT for male breast cancer with node-positive disease.
引用
- Abrams MJ, Koffer PP, Wazer DE, et al. Postmastectomy Radiation Therapy Is Associated With Improved Survival in Node-Positive Male Breast Cancer: A Population Analysis. Int J Radiat Oncol Biol Phys. 2017. PMID: 28463158. doi:10.1016/j.ijrobp.2017.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。